Invitrogen™ CD11a (LFA-1alpha) Monoclonal Antibody (R7.1), eBioscience™

Beskrivning

Description: This antibody specifically recognises CD11a, otherwise known as integrin alpha L chain. Clone R7.1 recognises an epitope within the I-domain of CD11a and can be used in neutralization studies. BMS102 is also suitable as primary antibody in staining for FACS analysis, BMS102FI can be used for direct staining of cells, BMS102BT can be used in a 2-step procedure using the biotin-(strept)avidin system. CD11a is a 180kDa glycoprotein and member of the integrin family of cell adhesion molecules, which is expressed by all human leukocytes.CD11a combines with the CD18 beta chain (ITGB2) to form lymphocyte function-associated antigen-1 (LFA-1), and binds to its major ligands CD50 (ICAM3), CD54 (ICAM1) and CD102 (ICAM2), acting as a key mediator of cell-cell adhesion processes in normal immune and inflammatory responses. Applications Tested: Flow Cytometry, Functional Studies (Blocking), Immunohistochemistry. Purity: >95%.

CD11a (LFA-1 alpha, ITGAL) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin. CD11a is implicated in activation of LFA-1 complex. CD11a plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. CD11a is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of CD11a to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. CD11a is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of CD11a function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti- CD11a antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity. Two transcript variants encoding different isoforms of CD11a have been found. Diseases associated with CD11a dysfunction include benign cephalic histiocytosis and leukocyte adhesion deficiency.